Use of aliskiren in Latin America in a real-world setting: Aliskiren in Latin America Study (ALAS)

Conclusion:
The BP reduction levels and the low adverse event rate demonstrate the adequate efficacy and safety profile of aliskiren (alone or with hydrochlorothiazide).

Source: Therapeutic Advances in Cardiovascular Disease - July 18, 2013 Category: Cardiology Authors: Volman, S., Benitez, F. N., Cedenio, H., Giorgi, M., Jaramillo, N., Molina, N., Zilberman, J. Tags: Original Research Source Type: research